Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SBIR reauthorization

Executive Summary

Companies seeking Small Business Innovation Research program grant money could be majority-owned by venture capital outfits under the SBIR/STTR Reauthorization Act, S. 3362, approved by the Senate Committee on Small Business and Entrepreneurship July 30. A similar measure was passed by the full House on April 23 (1"The Pink Sheet," April 28, 2008, p. 27). Industry has complained that restrictions on SBIR grants for VC-funded firms detract from the value of the federal program that helps jump-start small company research. The Senate bill would allow no more than 18 percent of National Institutes of Health SBIR funds to go to firms that are majority-owned by venture capitalists

You may also be interested in...

Revamp Of Small Business Funding Scheme Set For Yet Another Delay By Congress

SBIR update: House and Senate can't agree in time on bill prized by cash-hungry biotech industry. End-of-January deadline is set to slide.

House Passes SBIR Reauthorization, Loosens Venture Capital Restrictions

A bill reauthorizing the Small Business Innovation Research program cleared the House April 23, authorizing larger research and development grants from the federal government for small companies and lifting some restrictions on venture capital backing for firms seeking such grants

QUOTED. 6 May 2020. Paul Diaz.

Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts